- The Little Clinic adds new insurance provider to accepted plans
- Gallup: Take Care Clinics top in customer service
- Bartell to cease filling Medicaid prescriptions at 15 locations
- More progress needed in health information technology
- Rite Aid takes a bite out of obesity; relaunches weight-loss program for New Year
BRIDGEWATER, N.J. The Food and Drug Administration has approved a new formulation of a chemotherapy drug made by Sanofi-Aventis, the French drug maker said Thursday.
The FDA approved a one-vial version of the drug Taxotere (docetaxel) injection concentrate. The drug is expected to become available in clinics and hospitals nationwide this fall in 80-mg and 20-mg dosages, Sanofi said. The drug is used to treat cancers of the breast, prostate, lungs, head and neck and stomach.
“This new formulation underscores the commitment Sanofi-Aventis has made to Taxotere and to healthcare professionals,” Sanofi VP and oncology business unit head Paul Hawthorne said. “We look forward to adding this formulation of Taxotere to the aresenal of oncology products Sanofi-Aventis offers to the cancer community.”